SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
217 hedge funds and large institutions have $3.85B invested in SpringWorks Therapeutics in 2024 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 84 increasing their positions, 55 reducing their positions, and 25 closing their positions.
1,771% more call options, than puts
Call options by funds: $28.8M | Put options by funds: $1.54M
148% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 25
53% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 55
39% more capital invested
Capital invested by funds: $2.77B → $3.85B (+$1.08B)
21% more funds holding
Funds holding: 180 → 217 (+37)
0.71% more ownership
Funds ownership: 105.37% → 106.09% (+0.71%)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$107M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$61.7M |
| 3 |
Millennium Management
New York
|
+$31M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$31M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
+$24.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$69.9M |
| 2 |
DM
Deerfield Management
New York
|
-$60.2M |
| 3 |
MC
Maverick Capital
Dallas,
Texas
|
-$44.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$31.1M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$27M |
SWTX Hedge Fund Activity: Q1 2024 in Review
217 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q1 2024, worth a combined $3.85B — up 39% from $2.77B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new SWTX positions and 25 closed out — a net gain of 37 holders — while 84 added to existing stakes and 55 trimmed.
The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $107M. The largest seller was OrbiMed, cutting an estimated $69.9M.
- 217 institutional investors held SpringWorks Therapeutics (SWTX) as of Q1 2024, up from 180 in Q4 2023.
- Funds reported $3.85B of SpringWorks Therapeutics stock for Q1 2024, up 39% quarter-over-quarter.
- 62 funds opened new SpringWorks Therapeutics positions in Q1 2024 and 25 closed out, a net change of +37 holders.
- The largest SpringWorks Therapeutics buyer in Q1 2024 was Lord, Abbett & Co, an estimated $107M added.
- The largest SpringWorks Therapeutics seller in Q1 2024 was OrbiMed, an estimated $69.9M sold.
Based on aggregated 13F filings for Q1 2024.